Genome engineering through CRISPR/Cas9 technology in the human germline and pluripotent stem cells

Human Reproduction Update

Volumn 22, Issue 4, 2016, Pages 411-419

  Vassena, R ^a   Heindryckx, B ^b   Peco, R ^c   Pennings, G ^d   Raya, A ^c,e,f   Sermon, K ^g   Veiga, A ^c,h  

^a Clinica EUGIN   (Spain)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c CENTER OF REGENERATIVE MEDICINE IN BARCELONA   (Spain)

^d GHENT UNIVERSITY   (Belgium)

^e INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^f BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^g VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^h HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

CRISPR Cas9; Genome editing; Germline modification; Human embryo; Oocyte; Sperm; Stem cells

Indexed keywords

MITOCHONDRIAL DNA; TRANSCRIPTION ACTIVATOR LIKE EFFECTOR NUCLEASE; CRISPR ASSOCIATED PROTEIN;

ADAPTIVE IMMUNITY; ARTICLE; CELL DIFFERENTIATION; CLINICAL EFFECTIVENESS; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEAT; DNA CLEAVAGE; DNA MODIFICATION; DNA SEQUENCE; DOUBLE STRANDED DNA BREAK; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENE THERAPY; GENETIC ENGINEERING; GERMLINE STEM CELL; HOMOLOGOUS RECOMBINATION; HOMOZYGOSITY; HUMAN; LIFE EXPECTANCY; MEDICAL ETHICS; PATIENT SAFETY; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; RNA SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; ANIMAL; CRISPR CAS SYSTEM; EMBRYO DEVELOPMENT; ETHICS; GENE EDITING; GENETICS; PHYSIOLOGY; PROCEDURES; RNA EDITING;

ANIMALS; CLUSTERED REGULARLY INTERSPACED SHORT PALINDROMIC REPEATS; CRISPR-ASSOCIATED PROTEINS; CRISPR-CAS SYSTEMS; EMBRYONIC DEVELOPMENT; GENE EDITING; HUMANS; RNA EDITING;

EID: 84976340613     PISSN: 13554786     EISSN: 14602369     Source Type: Journal    
DOI: 10.1093/humupd/dmw005     Document Type: Article

References (73)

1. Araki M, Ishii T. International regulatory landscape and integration of corrective genome editing into in vitro fertilization. Reprod Biol Endocrinol 2014;12:108.
2. Barrangou R, Fremaux C, Deveau H, Richards M, Boyaval P, Moineau S, Romero DA, Horvath P. CRISPR provides acquired resistance against viruses in prokaryotes. Science 2007;315:1709-1712.
3. Bikard D, Jiang W, Samai P, Hochschild A, Zhang F, Marraffini LA. Programmable repression and activation of bacterial gene expression using an engineered CRISPR-Cas system. Nucleic Acids Res 2013;41:7429-7437.
4. Bioethics NCo. Novel techniques for the preservation of mitochondrial DNA disorders: an ethical review. Nuffield Council on Bioethics 2012.
5. Byrne SM, Ortiz L, Mali P, Aach J, Church GM. Multi-kilobase homozygous targeted gene replacement in human induced pluripotent stem cells. Nucleic Acids Res 2015;43:e21.
6. Carroll JM, Quaid KA, Stone K, Jones R, Schubert F, Griffith CB. Twois better than one: a case of homozygous myotonic dystrophy type 1. Am J Med Genet A 2013; 161A:1763-1767.
7. Collins FS. Statement on NIH funding of research using gene-editing technologies in human embryos. National Institutes of Health 2015.
8. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA et al. Multiplex genome engineering using CRISPR/Cas systems. Science 2013;339:819-823.
9. Chen F, Pruett-Miller SM, Davis GD. Gene editing using ssODNs with engineered endonucleases. Methods Mol Biol 2015;1239:251-265.
10. Deng W, Shi X, Tjian R, Lionnet T, Singer RH. CASFISH: CRISPR/Cas9-mediated in situ labeling of genomic loci in fixed cells. Proc Natl Acad Sci USA 2015; 112:11870-11875.
11. Dondorp W, de Wert G. Innovative reproductive technologies: risks and responsibilities. Hum Reprod 2011;26:1604-1608.
12. Donoho G, Jasin M, Berg P. Analysis of gene targeting and intrachromosomal homologous recombination stimulated by genomic double-strand breaks in mouse embryonic stem cells. Mol Cell Biol 1998;18:4070-4078.
13. Friedmann T, Jonlin EC, King NM, Torbett BE, Wivel NA, Kaneda Y, Sadelain M. ASGCT and JSGT joint position statement on human genomic editing. Mol Ther 2015;23:1282.
14. Guenther CA, Tasic B, Luo L, Bedell MA, Kingsley DM. A molecular basis for classic blond hair color in Europeans. Nat Genet 2014;46:748-752.
15. Haites N, Lovell-Badge R. Scientific reviewof the safety and efficacy of methods to avoid mitochondrial disease through assisted conception. Report provided to the Human Fertilisation and Embryology Authority 2011; 45.
16. Hatada S, Subramanian A, Mandefro B, Ren S, Kim HW, Tang J, Funari V, Baloh RH, Sareen D, Arumugaswami V et al. Low-dose irradiation enhances gene targeting in human pluripotent stem cells. Stem Cells Transl Med 2015;4:998-1010.
17. Hayashi K, Ohta H, Kurimoto K, Aramaki S, Saitou M. Reconstitution of the mouse germ cell specification pathway in culture by pluripotent stem cells. Cell 2011; 146:519-532.
18. Hayashi K, Ogushi S, Kurimoto K, Shimamoto S, Ohta H, Saitou M. Offspring from oocytes derived from in vitro primordial germ cell-like cells in mice. Science 2012; 338:971-975.
19. Hendel A, Bak RO, Clark JT, Kennedy AB, Ryan DE, Roy S, Steinfeld I, Lunstad BD, Kaiser RJ, Wilkens AB et al. Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells. Nat Biotechnol 2015; 33:985-989.
20. Heo YT, Quan X, Xu YN, Baek S, Choi H, Kim NH, Kim J. CRISPR/Cas9 nucleasemediated gene knock-in in bovine-induced pluripotent cells. Stem Cells Dev 2015; 24:393-402.
21. Hinxton. Statement on Genome Editing Technologies and Human Germline Genetic Modification. The Hinxton Group hinxtongroup.org 2015. Hurlbut. CRISPR Democracy: Gene Editing and the Need for Inclusive Deliberation. Issues Sci Technol 2015;32(1).
22. Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012; 337:816-821.
23. Kaiser J, Normile D. Bioethics. Embryo engineering study splits scientific community. Science 2015;348:486-487.
24. Lander ES. Brave new genome. N Engl J Med 2015;373:5-8.
25. Lanphier E, Urnov F, Haecker SE, Werner M, Smolenski J. Don't edit the human germ line. Nature 2015;519:410-411.
26. Li H, Haurigot V, Doyon Y, Li T, Wong SY, Bhagwat AS, Malani N, Anguela XM, Sharma R, Ivanciu L et al. In vivo genome editing restores haemostasis in a mouse model of haemophilia. Nature 2011;475:217-221.
27. Liang P, Xu Y, Zhang X, Ding C, Huang R, Zhang Z, Lv J, Xie X, Chen Y, Li Y et al. CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes. Protein Cell 2015a;6:363-372.
28. Liang X, Potter J, Kumar S, Zou Y, Quintanilla R, Sridharan M, Carte J, Chen W, Roark N, Ranganathan S et al. Rapid and highly efficient mammalian cell engineering via Cas9 protein transfection. J Biotechnol 2015b;208:44-53.
29. Liu Y, Lv X, Tan R, Liu T, Chen T, Li M, Liu Y, Nie F, Wang X, Zhou P et al. A modified TALEN-based strategy for rapidly and efficiently generating knockout mice for kidney development studies. PLoS One 2014;9:e84893.
30. Long C, Amoasii L, Mireault AA, McAnally JR, Li H, Sanchez-Ortiz E, Bhattacharyya S, Shelton JM, Bassel-Duby R, Olson EN. Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy. Science 2016; 351:400-403.
31. Macia A, Munoz-Lopez M, Cortes JL, Hastings RK, Morell S, Lucena-Aguilar G, Marchal JA, Badge RM, Garcia-Perez JL. Epigenetic control of retrotransposon expression in human embryonic stem cells. Mol Cell Biol 2011;31:300-316.
32. Mali P, Aach J, Stranges PB, Esvelt KM, Moosburner M, Kosuri S, Yang L, ChurchGM. CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nat Biotechnol 2013a; 31:833-838.
33. Mali P, Yang L, Esvelt KM, Aach J, Guell M, DiCarlo JE, Norville JE, Church GM. RNA-guided human genome engineering via Cas9. Science 2013b;339: 823-826.
34. Mandal PK, Ferreira LM, Collins R, Meissner TB, Boutwell CL, Friesen M, Vrbanac V, Garrison BS, Stortchevoi A, Bryder D et al. Efficient ablation of genes in human hematopoietic stem and effector cells using CRISPR/Cas9. Cell Stem Cell 2014; 15:643-652.
35. Mansour SL, Thomas KR, Capecchi MR. Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes. Nature 1988;336:348-352.
36. Meyn MS. High spontaneous intrachromosomal recombination rates in ataxiatelangiectasia. Science 1993;260:1327-1330.
37. Miller JC, Tan S, Qiao G, Barlow KA, Wang J, Xia DF, Meng X, Paschon DE, Leung E, Hinkley SJ et al. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 2011;29:143-148.
38. Mojica FJ, Diez-Villasenor C, Garcia-Martinez J, Soria E. Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol 2005;60:174-182.
39. Moreno-Mateos MA, Vejnar CE, Beaudoin JD, Fernandez JP, Mis EK, Khokha MK, Giraldez AJ. CRISPRscan: designing highly efficient sgRNAs for CRISPR-Cas9 targeting in vivo. Nat Methods 2015;12:982-988.
40. Newson AJ, Wrigley A. Identifying key developments, issues and questions relating to techniques of genome editing with engineered nucleases. Background paper. London: Nuffield Council on Bioethics, 2015.
41. Nickkholgh B, Mizrak SC, van Daalen SK, Korver CM, Sadri-Ardekani H, Repping S, van Pelt AM. Genetic and epigenetic stability of human spermatogonial stem cells during long-term culture. Fertil Steril 2014;102:1700-1707 e1701.
42. Niu J, Zhang B, Chen H. Applications of TALENs and CRISPR/Cas9 in human cells and their potentials for gene therapy. Mol Biotechnol 2014;56:681-688.
43. Park J, Bae S, Kim JS. Cas-Designer: a web-based tool for choice of CRISPR-Cas9 target sites. Bioinformatics 2015;31:4014-4016.
44. Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA. Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 2013;152:1173-1183.
45. QinW, Dion SL, Kutny PM, Zhang Y, Cheng AW, Jillette NL, Malhotra A, Geurts AM, Chen YG, Wang H. Efficient CRISPR/Cas9-mediated genome editing in mice by zygote electroporation of nuclease. Genetics 2015;200:423-430.
46. Ran FA, Hsu PD, LinCY, Gootenberg JS, Konermann S, Trevino AE, Scott DA, Inoue A, Matoba S, Zhang Y et al. Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. Cell 2013;154:1380-1389.
47. Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, Zetsche B, Shalem O, Wu X, Makarova KS et al. In vivo genome editing using Staphylococcus aureus Cas9. Nature 2015;520:186-191.
48. Reddy P, Ocampo A, Suzuki K, Luo J, Bacman SR, Williams SL, Sugawara A, OkamuraD, Tsunekawa Y, Wu J et al. Selective elimination of mitochondrial mutations in the germline by genome editing. Cell 2015;161:459-469.
49. Sato M, Koriyama M, Watanabe S, Ohtsuka M, SakuraiT, Inada E, Saitoh I, Nakamura S, Miyoshi K. Direct injection of CRISPR/Cas9-related mRNA into cytoplasm of parthenogenetically activated porcine oocytes causes frequent mosaicism for indel mutations. Int J Mol Sci 2015;16:17838-17856.
50. Schumann K, Lin S, Boyer E, Simeonov DR, Subramaniam M, Gate RE, Haliburton GE, Ye CJ, Bluestone JA, Doudna JA et al. Generation of knock-in primary human T cells using Cas9 ribonucleoproteins. Proc Natl Acad Sci USA 2015;112:10437-10442.
51. Shao Y, Guan Y, Wang L, Qiu Z, Liu M, Chen Y, Wu L, Li Y, Ma X, LiuMet al. CRISPR/ Cas-mediated genome editing in the rat via direct injection of one-cell embryos. Nat Protoc 2014;9:2493-2512.
52. Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F. Rationally engineered Cas9 nucleases with improved specificity. Science 2016;351:84-88.
53. Smithies O, Gregg RG, Boggs SS, Koralewski MA, Kucherlapati RS. Insertion of DNA sequences into the human chromosomal beta-globin locus by homologous recombination. Nature 1985;317:230-234.
54. Sugarman J. Ethics and germline gene editing. EMBO Rep 2015;16:879-880.
55. Symington LS, Gautier J. Double-strand break end resection and repair pathway choice. Annu Rev Genet 2011;45:247-271.
56. Tabebordbar M, Zhu K, Cheng JK, ChewWL, Widrick JJ, Yan WX, Maesner C, Wu EY, Xiao R, RanFAet al. In vivo gene editing in dystrophic mouse muscle and muscle stem cells. Science 2016;351:407-411.
57. Thakore PI, D'Ippolito AM, Song L, Safi A, Shivakumar NK, Kabadi AM, Reddy TE, Crawford GE, Gersbach CA. Highly specific epigenome editing by CRISPR-Cas9 repressors for silencing of distal regulatory elements. Nat Methods 2015; 12:1143-1149.
58. Thomas KR, Capecchi MR. Introduction of homologous DNA sequences into mammalian cells induces mutations in the cognate gene. Nature 1986;324:34-38.
59. Thomas KR, Folger KR, Capecchi MR. High frequency targeting of genes to specific sites in the mammalian genome. Cell 1986;44:419-428.
60. Torres R, Martin MC, Garcia A, Cigudosa JC, Ramirez JC, Rodriguez-Perales S. Engineering human tumour-associated chromosomal translocations with the RNA-guided CRISPR-Cas9 system. Nat Commun 2014;5:3964.
61. UNESCO International Bioethics Committee. Report of the IBC on Updating its reflection on the human genome and human rights. Paris, 2 October 2015.
62. Urnov FD, Miller JC, Lee YL, Beausejour CM, Rock JM, Augustus S, Jamieson AC, Porteus MH, Gregory PD, Holmes MC. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005;435:646-651.
63. van der Weyden L, Shaw-Smith C, Bradley A. Chromosome engineering in ES cells. Methods Mol Biol 2009;530:49-77.
64. Vassena R, Eguizabal C, Heindryckx B, Sermon K, Simon C, van Pelt AM, Veiga A, Zambelli F, Cells Esig S. Stem cells in reproductive medicine: ready for the patient? Hum Reprod 2015;30:2014-2021.
65. Wang S, Yi F, Qu J. Eliminate mitochondrial diseases by gene editing in germ-line cells and embryos. Protein Cell 2015;6:472-475.
66. WuY, Liang D, Wang Y, Bai M, Tang W, Bao S, Yan Z, Li D, Li J. Correction of a genetic disease in mouse via use of CRISPR-Cas9. Cell Stem Cell 2013;13:659-662.
67. Wu Y, Zhou H, Fan X, Zhang Y, Zhang M, Wang Y, Xie Z, Bai M, Yin Q, Liang D et al. Correction of a genetic disease by CRISPR-Cas9-mediated gene editing in mouse spermatogonial stem cells. Cell Res 2015;25:67-79.
68. Yen ST, Zhang M, Deng JM, Usman SJ, Smith CN, Parker-Thornburg J, Swinton PG, Martin JF, Behringer RR. Somatic mosaicism and allele complexity induced by CRISPR/Cas9 RNA injections in mouse zygotes. Dev Biol 2014;393:3-9.
69. Yoshimi K, Kaneko T, Voigt B, Mashimo T. Allele-specific genome editing and correction of disease-associated phenotypes in rats using the CRISPR-Cas platform. Nat Commun 2014;5:4240.
70. Yu C, Liu Y, Ma T, Liu K, Xu S, Zhang Y, Liu H, La Russa M, Xie M, Ding S et al. Small molecules enhance CRISPR genome editing in pluripotent stem cells. Cell Stem Cell 2015;16:142-147.
71. Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS, Essletzbichler P, Volz SE, Joung J, van der Oost J, Regev A et al. Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell 2015;163:759-771.
72. Zhong C, Yin Q, Xie Z, Bai M, Dong R, TangW, Xing YH, Zhang H, Yang S, Chen LL et al. CRISPR-Cas9-mediated genetic screening in mice with haploid embryonic stem cells carrying a guide RNA library. Cell Stem Cell 2015;17:221-232.
73. Zou Q, Wang X, Liu Y, Ouyang Z, Long H, Wei S, Xin J, Zhao B, Lai S, Shen J et al. Generation of gene-target dogs using CRISPR/Cas9 system. J Mol Cell Biol 2015; 7:580-583.